2-hydroxy Flutamide
CAS No. 52806-53-8
2-hydroxy Flutamide( —— )
Catalog No. M20966 CAS No. 52806-53-8
2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 42 | Get Quote |
|
10MG | 72 | Get Quote |
|
25MG | 140 | Get Quote |
|
50MG | 215 | Get Quote |
|
100MG | 335 | Get Quote |
|
200MG | 494 | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name2-hydroxy Flutamide
-
NoteResearch use only, not for human use.
-
Brief Description2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.
-
Description2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research AreaCancer
-
IndicationProstate Cancer
Chemical Information
-
CAS Number52806-53-8
-
Formula Weight292.21
-
Molecular FormulaC11H11F3N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:25mg/ml(85.5 mM)
-
SMILESCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
-
Chemical Name2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Blobaum A L Byers F W Bridges T M et al. A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals 2015 43(11):1718.
molnova catalog
related products
-
YK11
YK11 is an androgen receptor partial agonist that activates androgen receptor transcriptional activity in HEK293 cells overexpressing androgen receptors when used at a concentration of 0.1 μM with osteogenic activity.
-
LGD-3303
LGD-3303 is an orally available, brain-penetrant nonsteroidal selective androgen receptor modulator (SARM) that that shows little or no cross-reactivity with related nuclear receptors.
-
LY305
LY305 (LY-305) is a non-steroidal selective androgen receptor modulator (SARM) with Ki of 2.03 nM.